首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
【24h】

Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.

机译:新型3,4,5-三甲氧基苄基苯并咪唑衍生物的合成和生物评价,可抑制幽门螺杆菌在人胃上皮细胞中诱发的发病机理。

获取原文
获取原文并翻译 | 示例
           

摘要

Helicobacter pylori infection is associated with gastritis, peptic ulcer, and even gastric malignancy. H.?pylori's antibiotic resistance is the major obstacle preventing its eradication. A series of 3,4,5-trimethoxybenzylbenzimidazole derivatives were synthesized and evaluated for their anti-H. pylori activity. The compound, 2-fluorophenyl-5-methyl-1-(3,4,5-trimethoxybenzyl)benzimidazole (FMTMB), was determined as the most potent in the inhibition of H.?pylori growth and pathogenesis of host cells. An in?vitro H. pylori infection model revealed that FMTMB inhibited H.?pylori adhesion and invasion of gastric epithelial cells. Results from this study provide evidence that FMTMB is a potent therapeutic agent that exhibits both anti-H.?pylori growth properties and anti-H.?pylori-induced pathogenesis of cells.
机译:幽门螺杆菌感染与胃炎,消化性溃疡甚至胃恶性肿瘤有关。幽门螺杆菌的抗药性是阻止其根除的主要障碍。合成了一系列的3,4,5-三甲氧基苄基苯并咪唑衍生物,并评估了它们的抗-H。幽门螺杆菌活动。化合物2-氟苯基-5-甲基-1-(3,4,5-三甲氧基苄基)苯并咪唑(FMTMB)被确定为抑制幽门螺杆菌生长和宿主细胞发病机理中最有效的化合物。体外幽门螺杆菌感染模型显示,FMTMB抑制幽门螺杆菌粘附和侵袭胃上皮细胞。这项研究的结果提供了证据,表明FMTMB是一种有效的治疗剂,具有抗幽门螺杆菌的生长特性和抗幽门螺杆菌诱导的细胞发病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号